BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35732498)

  • 21. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
    Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
    Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer.
    Xie F; Zheng X; Mao X; Zhao R; Ye J; Zhang Y; Sun J
    Ann Thorac Surg; 2019 Jul; 108(1):219-226. PubMed ID: 30885850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
    Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
    Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib.
    Ding PN; Becker T; Bray V; Chua W; Ma Y; Xu B; Lynch D; de Souza P; Roberts T
    Thorac Cancer; 2019 Oct; 10(10):1879-1884. PubMed ID: 31414729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
    He C; Wei C; Wen J; Chen S; Chen L; Wu Y; Shen Y; Bai H; Zhang Y; Chen X; Li X
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):321-330. PubMed ID: 34693477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of a 50-gene next generation sequencing panel with post-centrifuge supernatant cytology fluid in non-small-cell lung cancer.
    Tafoya M; Judd A; Chiotti K; Dearen K; Jiron K; Chabot-Richards D; Broehm CJ
    Diagn Cytopathol; 2021 Nov; 49(11):1173-1178. PubMed ID: 34339108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.
    Blombery P; Jones K; Doig K; Ryland G; McBean M; Thompson E; Yannakou CK; Westerman D
    Arch Pathol Lab Med; 2018 May; 142(5):606-612. PubMed ID: 29425073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytology meets next generation sequencing and liquid biopsy: A case of lung adenocarcinoma presenting as metastasis to the phalanx.
    Clery E; Pisapia P; Migliatico I; Pepe F; De Luca C; Russo M; De Rosa F; Smeraglia F; Insabato L; Vigliar E; Malapelle U; Mariconda M; Gridelli C; Troncone G
    Diagn Cytopathol; 2020 Aug; 48(8):759-764. PubMed ID: 32320137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
    Scilla KA; Rolfo C
    Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.
    Bennett CW; Berchem G; Kim YJ; El-Khoury V
    Oncotarget; 2016 Oct; 7(43):71013-71035. PubMed ID: 27589834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer.
    Prabhash K; Biswas B; Khurana S; Batra U; Biswas G; Advani SH; Mohapatra PN; Rajappa S; Sharma A; Patil S; Dattatreya PS; Roy R; Almel S; Goyal G; Warrier N
    Indian J Cancer; 2022 Mar; 59(Supplement):S11-S18. PubMed ID: 35343188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
    Zheng Y; Vioix H; Liu FX; Singh B; Sharma S; Sharda D
    Future Oncol; 2022 Feb; 18(4):505-518. PubMed ID: 34865516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.
    Luthra R; Patel KP; Reddy NG; Haghshenas V; Routbort MJ; Harmon MA; Barkoh BA; Kanagal-Shamanna R; Ravandi F; Cortes JE; Kantarjian HM; Medeiros LJ; Singh RR
    Haematologica; 2014 Mar; 99(3):465-73. PubMed ID: 24142997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integration of Liquid Biopsies into Clinical Laboratory Applications via NGS in Cancer Diagnostics.
    Sonmezler O; Boga I; Bisgin A
    Clin Lab; 2020 May; 66(5):. PubMed ID: 32390404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
    Au CH; Wa A; Ho DN; Chan TL; Ma ES
    Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.